Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel | BMC Cancer | Full Text

Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel | BMC Cancer | Full Text

Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel

In recent years treatment options for advanced pancreatic cancer have markedly improved, and a combination regimen of gemcitabine and nab-paclitaxel is now considered standard of care in Sweden and elsewhere. ...

Authors:Hakon Blomstrand, Henrik Green, Mats Fredrikson, Emma Gränsmark, Bergthor Björnsson and Nils O. Elander

Citation:BMC Cancer 2020 20:950

Content type:Research article

 

Published on: 2 October 2020

• ViewFull Text
 
• ViewPDF